MIRA INFORM REPORT

 

 

Report Date :

12.11.2007

 

IDENTIFICATION DETAILS

 

Name :

TABROS PHARMA

 

 

Registered Office :

Essa House 32 – 1/C, Block 6, P.E.C.H.S., Karachi

 

 

Country :

Pakistan

 

 

Date of Incorporation :

1971

 

 

Com. Reg. No.:

0277826

 

 

Legal Form :

Proprietorship

 

 

Line of Business :

Manufacture & marketing of different pharmaceutical class

 

 

RATING & COMMENTS

 

MIRA’s Rating :

Ba

 

RATING

STATUS

PROPOSED CREDIT LINE

41-55

Ba

Overall operation is considered normal. Capable to meet normal commitments.

Satisfactory

 

Status :

Satisfactory

 

 

Payment Behaviour :

Regular

 

 

Litigation :

Clear

 

 

 

Business Name

 

TABROS PHARMA

 

 

Full Address       

 

Registered Address

Essa House, 32-1/C, Block-6, P.E.C.H.S., Karachi, Pakistan

                       

Tel

92 (21) 4533418, 4533416

Fax

92 (21) 4532898

Email

tabroz@super.net.pk

 

 

 

Short Description Of Business

 

 

Nature of Business           

Manufacture & Marketing  of Pharmaceutical Products

 

Year Established

1971

 

National Tax #

0277826

 

 

 

Factory Location

 

Address

L-20/B, Sector-22, Federal B Industrial Area, Karachi, Pakistan

Tel #

92 (21) 6360631, 6366789

Fax #

92 (21) 6365425

 

 

 

Legal Status

 

Subject Company was established as a Proprietorship business in 1971

 

 

 

Details of Proprietor

 

Names

Nationality

Address

Occupation

Designation

Mr. Muhammad Abdullah Essa

 

Pakistani

 

 

Essa House, 32-1/C, Block-6, P.E.C.H.S., Karachi, Pakistan

Business

 

 

Proprietor

 

 

 

 

 

Associates                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     

 

A.         Subsidiary

 

            None                                            

           

B.         Associated Companies

 

            - Do -

 

 

Products

 

Manufacture & marketing of different pharmaceutical class like Anti Biotic, Anti Malarials, Anti-Rheumatic, Antihistamine, Narcotic Analgesic, Non Steroidal Respiratory Anti Inflamatory, Quinolones, Vitamins, Phenothiazine, Hypolipidaemics, Muscle Relaxant, Amoebicide, Calcium-Antagonist, Cardio Selective Beta Blocker with their brand names of AMYGRA, ARIX, ARTEMAL, CALIX, CEFON, DURAGESIC, DURAZANIL, E-CLAR, FENAC, FERRY, FERRY-F, FIXITIL, FIXITIL-T, FLENCH, FOCIN, FUSIL, FUSIL-B, FUSIL-HC, G-MET, GAVEL, HEMSAMIC, KLIC, KLIC-F, METEOSPASMYL, OPTIMOL, ORIBRO, ORPHINE, PANTONIL, PECTUS, PROGREL, RONIL, RUMOLON, RUMOLON INJ, SPADIX, TABROMIDE, TABROPHAGE, TABROXACIN, TONICARD, V-PAN, VADIL, VIZOR, ZATRON, ZEEST, ZISCAR 

 

           

Number of Employees

 

233      

 

 

Annual Production Volume

 

The capacity and production of the company’s plant is indeterminable as it is multi-product and involves varying processes of manufacture

 

 

Annual Sales Volume

 

Year

In Pak Rupees

2006

350,000,000/- (Estimated)

 

 

 

Agencies (Foreign)

 

(1) DAFRA PHARMA, BELGIUM

(2) INTER HEALTH, U.S.A.

(3) LONZA, SWITZERLAND.

(4) MAYOLY SPINDLER, FRANCE.

(5) UNIBIOS, ITALY.

(6) ALCON PHARMACEUTICALS, INDIA.

(7) NAN YA PLASTIC CORPORATION, SINGAPORE.

Distributors

 

More than 60 Distributors in all over Pakistan

 

 

Exporting Countries

 

Mainly to East Africa, South East Asia, Far East and CIS countries

 

 

Bankers

 

Faysal Bank Limited, Pakistan.

Soneri Bank Limited, Pakistan.

Habib Metropolitan Bank Limited, Pakistan.

Bank Alhabib Limited, Pakistan.

Standard Chartered Bank, Pakistan.

 

 

Memberships

 

Pakistan Pharmaceutical Manufacturers Association.

Karachi Chamber of Commerce & Industry.

 

 

Foreign Exchange Rates

 

Currency

 

Unit

Pakistani Rupee

US Dollar

1

Rs. 60.92

UK Pound

1

  Rs. 128.10

Euro

1

Rs. 89.20

 

 

Comments

 

Subject Company was established in 1971 and is engaged in manufacture & marketing of Pharmaceutical Products. Company’s market reputation is good. Trade relations are reported as fair. Subject can be considered for normal business dealings at usual trade terms and conditions.

 

 

 

 

 

 

 

 

 

 

 

 

RATING EXPLANATIONS

 

RATING

STATUS

 

 

PROPOSED CREDIT LINE

>86

Aaa

Possesses an extremely sound financial base with the strongest capability for timely payment of interest and principal sums

 

Unlimited

71-85

Aa

Possesses adequate working capital. No caution needed for credit transaction. It has above average (strong) capability for payment of interest and principal sums

 

Large

56-70

A

Financial & operational base are regarded healthy. General unfavourable factors will not cause fatal effect. Satisfactory capability for payment of interest and principal sums

 

Fairly Large

41-55

Ba

Overall operation is considered normal. Capable to meet normal commitments.

 

Satisfactory

26-40

B

Unfavourable & favourable factors carry similar weight in credit consideration. Capability to overcome financial difficulties seems comparatively below average.

 

Small

11-25

Ca

Adverse factors are apparent. Repayment of interest and principal sums in default or expected to be in default upon maturity

 

Limited with full security

<10

C

Absolute credit risk exists. Caution needed to be exercised

 

 

Credit not recommended

NR

In view of the lack of information, we have no basis upon which to recommend credit dealings

No Rating

 

 

This score serves as a reference to assess SC’s credit risk and to set the amount of credit to be extended. It is calculated from a composite of weighted scores obtained from each of the major sections of this report. The assessed factors and their relative weights (as indicated through %) are as follows:

 

Financial condition (40%)            Ownership background (20%)                 Payment record (10%)

Credit history (10%)                    Market trend (10%)                                Operational size (10%)

 

 

 

 

PRIVATE & CONFIDENTIAL : This information is provided to you at your request, you having employed MIPL for such purpose. You will use the information as aid only in determining the propriety of giving credit and generally as an aid to your business and for no other purpose. You will hold the information in strict confidence, and shall not reveal it or make it known to the subject persons, firms or corporations or to any other. MIPL does not warrant the correctness of the information as you hold it free of any liability whatsoever. You will be liable to and indemnify MIPL for any loss, damage or expense, occasioned by your breach or non observance of any one, or more of these conditions